| dc.contributor.author | Kayal, Maia | |
| dc.contributor.author | Shah, Shailja | |
| dc.date.accessioned | 2020-11-12T23:05:11Z | |
| dc.date.available | 2020-11-12T23:05:11Z | |
| dc.date.issued | 2020-01 | |
| dc.identifier.citation | Kayal, M., & Shah, S. (2019). Ulcerative Colitis: Current and Emerging Treatment Strategies. Journal of clinical medicine, 9(1), 94. https://doi.org/10.3390/jcm9010094 | en_US |
| dc.identifier.other | eISSN: 2077-0383 | |
| dc.identifier.uri | http://hdl.handle.net/1803/16286 | |
| dc.description.abstract | Historically, medical therapy for ulcerative colitis (UC) was limited to corticosteroids. Excitingly, over the past just 1-2 decades, the options for medical therapy have expanded and include biologics and small molecules, with more agents actively being developed. In this article, we review the current and emerging treatment strategies for UC stratified according to disease severity. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Journal of Clinical Medicine | en_US |
| dc.rights | Copyright © 2019 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | |
| dc.source.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019865/ | |
| dc.subject | ulcerative colitis | en_US |
| dc.subject | biologic | en_US |
| dc.subject | small molecule | en_US |
| dc.subject | colectomy | en_US |
| dc.title | Ulcerative Colitis: Current and Emerging Treatment Strategies | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.3390/jcm9010094 | |
